搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
Cure Today
10 小时
Side Effects, Quality of Life Important to Consider in Breast Cancer Subset
Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.
imt.ie
2 天
US oncologist Dr Dennis Slamon receives UCD medal
In presenting Dr Slamon with the Ulysses Medal, UCD recognises that his pursuit of novel therapies for breast cancer for over ...
2 天
Breast Cancer Chemotherapy – Here Is What Happened When Outrageous Prices Met The Free Market
Per Genentech, the current price of Herceptin for a patient with “HER2 positive metastatic breast cancer” as about $50,000, a ...
The Punch Newspapers
7 天
22-year-old LASU student battles cancer, family seeks N15m financial help
A 22-year-old LASU student is urgently seeking N15 million financial assistance as she battles an aggressive form of breast ...
Targeted Oncology
10 天
FDA Approves New Dosage of Trastuzumab Biosimilar for HER2-Overexpressing Cancers
Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...
GlobalData on MSN
10 天
FDA approves Accord BioPharma’s HERCESSI for cancer treatment
Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) ...
Monthly Prescribing Reference
12 天
Additional Dosage Strength of Biosimilar Hercessi Gets FDA Approval
The Food and Drug Administration (FDA) has approved a 420mg dosage strength of Hercessi ™ (trastuzumab-strf), a biosimilar to Herceptin ® (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...
Targeted Oncology
12 天
Tumor-Infiltrating Lymphocytes as Potential Predictors of Survival in Trastuzumab-Treated ...
In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in ...
precisionmedicineonline
13 天
'Vast Majority' of Cancer Patients Lack Access to Essential Drugs Despite Advances, Says ...
Using Herceptin as an example, Andre Ilbawi detailed the challenges low- and medium-income countries face in accessing essential therapies.
University of Cambridge
13 天
Monoclonal antibodies offer hope for tackling antimicrobial resistance
Monoclonal antibodies – treatments developed by cloning a cell that makes an antibody – could help provide an answer to the ...
FierceBiotech
13 天
ESMO: Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...
Cure Today
15 天
TILs May Predict Survival in Early HER2-Positive Breast Cancer Treated With Herceptin
High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈